

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

4. A compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.

5. A compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid salt form, for use in the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated facilitated by CRF.

6. A pharmaceutical composition comprising a compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

7. The use of a compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated facilitated by CRF.

8. The use of a compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated facilitated by CRF.

9. A method for the treatment of any state with increased endogenous level of CRF or in which the HPA is disregulated, or of a disease induced or facilitated facilitated by CRF in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 ~~or 2~~ in free base or pharmaceutically acceptable acid addition salt form.

2025 RELEASE UNDER E.O. 14176